Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2016, Article ID 7149821, 6 pages
http://dx.doi.org/10.1155/2016/7149821
Case Report

Neuroendocrine Cancer of Rectum Metastasizing to Ovary

1Department of OBG, Kasturba Medical College, Manipal University, Manipal 576104, India
2IVF and Reproductive Biology Centre, Maulana Azad Medical College, New Delhi 110002, India
3Department of Medical Oncology, Kasturba Medical College, Manipal University, Manipal 576104, India
4Department of Surgery, Kasturba Medical College, Manipal University, Manipal 576104, India
5Department of Pathology, Melaka Manipal Medical College, Manipal University, Manipal 576104, India

Received 21 November 2015; Revised 13 March 2016; Accepted 20 April 2016

Academic Editor: Jorg Kleeff

Copyright © 2016 Sapna Vinit Amin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Oberg and D. Castellano, “Current knowledge on diagnosis and staging of neuroendocrine tumors,” Cancer and Metastasis Reviews, vol. 30, supplement 1, pp. 3–7, 2011. View at Google Scholar
  2. J. D. Smith and G. Nandakumar, “Hindgut neuroendocrine neoplasia,” Indian Journal of Surgical Oncology, vol. 7, no. 1, pp. 73–78, 2016. View at Publisher · View at Google Scholar
  3. J. D. Smith, D. L. Reidy, K. A. Goodman, J. Shia, and G. M. Nash, “A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum,” Annals of Surgical Oncology, vol. 21, no. 9, pp. 2956–2962, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. F. T. Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise, World Health Organization Classification of Tumours of the Digestive System, IARC, Lyon, France, 2010.
  5. G. Rindi, G. Klöppel, H. Alhman et al., “TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system,” Virchows Archiv, vol. 449, no. 4, pp. 395–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W. D. Travis, E. Brambilla, H. K. Muller-Hermelink, and C. C. Harris, World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart, IARC, Lyon, France, 2004.
  7. M. H. Kulke, L. B. Anthony, D. L. Bushnell et al., “NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas,” Pancreas, vol. 39, no. 6, pp. 735–752, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. V. T. DeVita, T. S. Lawrence, and S. A. Rosenberg, Cancer—Principles and Practice of Oncology, Lippincott Williams and Wilkins, 8th edition, 2008.
  9. J. R. Strosberg, D. Coppola, D. S. Klimstra et al., “The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas,” Pancreas, vol. 39, no. 6, pp. 799–800, 2010. View at Publisher · View at Google Scholar
  10. J. Shia, L. H. Tang, M. R. Weiser et al., “Is non small cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?” The American Journal of Surgical Pathology, vol. 32, no. 5, pp. 719–731, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Strosberg, A. Nasir, D. Coppola, M. Wick, and L. Kvols, “Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors,” Human Pathology, vol. 40, no. 9, pp. 1262–1268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Yao, M. Hassan, A. Phan et al., “One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3063–3072, 2008. View at Publisher · View at Google Scholar
  13. A. Koumarianou, E. Chatzellis, G. Boutzios, N. Tsavaris, and G. Kaltsas, “Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas,” Endokrynologia Polska, vol. 64, no. 1, pp. 60–72, 2013. View at Google Scholar · View at Scopus
  14. C. M. Korse, J. M. G. Bonfrer, N. K. Aaronson et al., “Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors,” Neuroendocrinology, vol. 89, no. 3, pp. 296–301, 2009. View at Google Scholar
  15. P. Ferolla, A. Faggiano, G. Mansueto et al., “The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers,” Journal of Endocrinological Investigation, vol. 31, no. 3, pp. 277–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Brenner, M. A. Shah, M. Gonen, D. S. Klimstra, J. Shia, and D. P. Kelsen, “Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases,” British Journal of Cancer, vol. 90, no. 9, pp. 1720–1726, 2004. View at Google Scholar · View at Scopus
  17. J. Smith and D. Reidy-Lagunes, “The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas,” Seminars in Oncology, vol. 40, no. 1, pp. 100–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. G. Moertel, L. K. Kvols, M. J. O'Connell, and J. Rubin, “Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms,” Cancer, vol. 68, no. 2, pp. 227–232, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Mitry, E. Baudin, M. Ducreux et al., “Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin,” British Journal of Cancer, vol. 81, no. 8, pp. 1351–1355, 1999. View at Publisher · View at Google Scholar · View at Scopus